Leptin Infusion for Type 1 Diabetes

Abstract

Our mission is to ensure the proper leptin delivery system targets patients with type 1 diabetes, aiming to reduce systemic dosage delivery and benefit patients. Determined to lessen the long-term healthcare costs, this project promises improvements in patients’ overall health. The type 1 diabetes market has $15.95 billion in 2024 and in the U.S, a $24.36 billion growth of 6.2% within the years which shows major opportunity for a device. DialyCare offers a mechanical pump that uses a 50 mL reservoir where leptin (metreleptin) is transferred to a catheter that is connected to the cerebrospinal fluid. It is then dispensed over time with a dosage appropriate to the patient’s needs. Leptin is delivered using a perfluorodecalin gas (2-phase system) that helps push leptin to the CSF. Within the device, there are sensors which are encoded using CGM software that enables real-time tracking of catheter flow rate and precise delivery of leptin to the cerebrospinal fluid. We also proposed a lithium battery which lasts up to 10 years, ensuring longevity and a reliable power source. Our prototype will be made out of ABS filament due to its strength and durability for testing, while keeping costs low. The below component will be made out of medical grade platinum cured silicone. This silicone is quite flexible, has great resistance to our desired range of pressure, is safe, and biocompatible within the spinal environment. For our final version, we will use high-grade biocompatible materials, titanium, and medical-grade silicone.

Video